Monday, 03 April 2017
Ferring appoints Dominic Moorhead as Executive Vice President and Chief Financial Officer
Saint-Prex, Switzerland – 3rd April 2017 – Ferring Pharmaceuticals announced today that Dominic Moorhead has been appointed as Executive Vice President and Chief Financial Officer, effective 1st July 2017.
Moorhead succeeds Peter Wilden, who joined Ferring 25 years ago and was one of the original members of the Group Executive Board.
Following a three-month transition period, Moorhead will assume full responsibility for the Finance, Corporate Information Systems and Internal Audit functions of the global Ferring Group. Wilden will continue to represent Ferring on a number of additional Boards.
“Peter has been a guardian of Ferring’s financial integrity and stability, and we will look back with satisfaction on his exceptional career within the company,” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer of Ferring. “I am confident that Dominic will continue this track record of success. His extensive experience and perspectives in finance, business and strategic development in the pharmaceutical sector make him a great fit for Ferring as we continue on our strong growth path.”
Moorhead has 30 years’ finance and business experience in the life sciences industry. For the past year, he has been a strategic advisor to executives and investors in biotech. Before this, he worked for Takeda Pharmaceuticals for four years, as Global Financial Controller, and CFO of the International business following the acquisition of Nycomed. Prior to this he worked for Hoffmann-La Roche for 13 years, where he was CFO of the Pharma Division for nine years during a period of much challenge, transformation, and growth. He was engaged in numerous strategic initiatives and business transactions, as well as their operational implications, culminating in the privatization of Genentech in the U.S. in 2009.
- Ends -
About Ferring Pharmaceuticals:
Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com.
For further information:
Tel. +41 58 301 01 78
See more Press releases